Truveta’s Post

Via the Los Angeles Times: "In the first head-to-head comparison of two blockbuster drugs used in real-world conditions, people who took Mounjaro lost significantly more weight than their counterparts who took Ozempic — and the longer the patients kept taking the drugs, the wider the gap became." Read the LA Times' coverage of our comparative effectiveness study that was recently published in JAMA Internal Medicine: https://tr.vet/4cSIAhs #ComparativeEffectiveness #Mounjaro #Ozempic #Semaglutide #Tirzepatide #WeightLossDrugs #WeightLoss #HealthData #HealthTech #HealthAI #HealthcareAI #HealthInnovation #HealthcareInnovation #Innovation #AI #HealthData #HealthcareData #PrescriptionTrends #PrescriptionData #MedicalData #MedicalTechnology #MedTech

Now available via JAMA Internal Medicine: Truveta Research's study using real-world data on weight loss trends among patients with overweight or obesity taking tirzepatide (Mounjaro) versus semaglutide (Ozempic) found that those taking tirzepatide were 3.2x more likely than their counterparts taking semaglutide to achieve 15% weight loss. This is the largest comparative effectiveness study of its kind, and it's now peer-reviewed. Learn more: https://tr.vet/3XVCPeS #JAMA #JAMAInternalMedicine #PeerReviewed #MedicalJournal #Semaglutide #Tirzepatide #Ozempic #Mounjaro #WeightLossDrugs #WeightLoss #WeightLossTrend #BMI #ComparativeEffectiveness #HealthData #HealthcareData #HealthcareTrends #HealthTrends #HealthAI #HealthInnovation #AI #Innovation #MedicalData #PrescriptionTrends #PrescriptionData #MedicalTechnology #MedTech

Recently, Truveta Research released the latest installment of their GLP-1 RA monitoring report. The report shows that overall prescription rates and first-time prescriptions for medications that are now commonly being prescribed for weight loss, like semaglutide, tirzepatide, and others, aren't showing any signs of slowing down. Use your LinkedIn credentials to view the report in Truveta Studio: https://tr.vet/4eC6IXD #Semaglutide #Tirzepatide #Liraglutide #GLP1 #GLP1Data #GLP1PrescriptionTrends #PrescriptionTrends #PrescriptionData #HealthData #HealthTech #HealthcareData #HealthcareAI #HealthcareInnovation #AI #Innovation #LLM #MedicalResearch #MedicalTechnology #MedTech #WeightLoss #WeightLossDrugs

Truveta offers regulatory and audit capabilities to support customers in real-world evidence submissions to the FDA and other global regulatory authorities. RWE can clearly demonstrate real-life clinical performance, so we've invested in establishing: ✅rigorous standards of data quality and provenance, 📃workflow support for regulatory submissions, and 🔎audit-ready processes and controls to support life science orgs in meeting the most stringent regulatory requirements. Learn more: https://tr.vet/3Rx4qiG #RWE #RealWorldEvidence #RegulatoryGrade #RegulatorySubmission #FDA #FoodAndDrugAdministration #DataQuality #RealWorldData #RWD #HEOR #ClinicalTrials #LifeSciences #RegGrade

"Perinatal women and their children have historically been excluded from clinical trials and data sources... That hinders efforts to understand the full effects of medications, vaccines and diseases on outcomes. It is also difficult to study maternal-fetal health using claims data only..." Read more about the largest, most complete mother-child EHR dataset, now available in Truveta Data, via Fierce Healthcare senior writer Anastassia Gliadkovskaya: https://tr.vet/3UPpKla #MotherChildData #PediatricData #MaternalHealth #MaternalHealthData #PediatricHealthcare #PediatricOutcomes #HealthData #HealthcareData #HealthAI #HealthInnovation #HealthcareAI #HealthcareInnovation #AI #Innovation #MedicalData #MedicalInnovation #MedicalAI #EHRData #EHR

As #MensHealthMonth draws to a close, Truveta Research is sharing insights on prostate-specific antigen (PSA) screening recommendations, and how first-time PSA values vary across demographics and SDOH factors. Learn more: https://tr.vet/3VtJJFl #MensHealth #MensHealthMonth2024 #HealthcareData #Prostate #ProstateCancer #ProstateSpecificAntigen #PSAScreening #SocialDriversOfHealth #SocialDeterminantsOfHealth #HealthEquity #HealthcareData #HealthData #HealthAI #HealthInnovation #AI #Innovation #MedicalData #MedicalTechnology #MedTech

The US government has a goal of slashing new HIV infections by 90% by 2030 - but there's a huge need for more research into prevention and treatments, as well as generating more awareness, particularly among populations that are most at-risk. Use your LinkedIn credentials to view all the population data available to support HIV research in Truveta Studio, including nearly 600K patients, 304M labs, and 77K patients taking PrEP: https://tr.vet/4cnhBuE #HIV #HIVTreatment #HIVPrevention #AntiRetroVirals #ARTs #AntiRetroviralTherapy #PrEP #HealthData #MedicalData #HealthcareData #HIVData #HealthAI #HealthInnovation #HealthTech #AI #Innovation #HealthcareTech #HealthcareData #HealthcareAI #HealthcareInnovation #MedicalData #MedicalTechnology #MedTech #MedicalResearch #HIVResearch

Truveta Data delivers the largest and most complete mother-child EHR dataset, empowering researchers to study mothers and children through their pregnancy journeys and beyond. Learn more: https://tr.vet/3VsHeEl #MotherChildData #MotherChildHealth #MaternalHealth #PediatricHealth #PrenatalCare #PostnatalCare #HealthData #HealthcareData #HealthAI #HealthInnovation #HealthcareAI #HealthcareInnovation #AI #Innovation #MedicalData

Today our CTO Jay Nanduri spoke on a panel at Seattle University’s Ethics & Tech Conference about how technology can responsibly help the healthcare industry. Jay shared this guidance, which also informs how we’re training the Truveta Language Model: “An AI model is only as good as the data it’s trained on; if the data has bias, the model will have bias. So we need to take great care to ensure the most diverse, representative, quality data possible, to ensure our models are not biased.”